CLAIMS OF THE APPLICATION:

1. (Original) A tablet comprising a drug substance that is susceptible to polymorphic conversion, the tablet having been formed by compression with forces sufficiently low to maintain the drug in its original polymorphic form.

2. (Original) The tablet according to claim 1, wherein the drug substance is amorphous.

3. (Original) The tablet according to claim 2, wherein no greater than about 10 weight percent of the amorphous drug substance is crystalline.

4. (Original) The tablet according to claim 1, wherein compression is conducted between about 0.2 and about 5 tons.

5. (Original) The tablet according to claim 1, wherein compression is conducted between about 0.2 and about 3 tons.

6. (Original) The tablet according to claim 1, wherein a maximum tablet dimension is about 3 mm.

7. (Original) The tablet according to claim 1, wherein a maximum tablet dimension is about 1 mm to about 3 mm.

8. (Original) A pharmaceutical dosage form comprising a plurality of tablets prepared according to claim 1, contained within a capsule.

9. (Original) A pharmaceutical dosage form, comprising a plurality of particles formed by:

(a) mixing a drug substance that is susceptible to polymorphic conversion, with one or more pharmaceutically acceptable excipients;

(b) compressing the mixture at about 0.2 tons to about 5 tons, to form particles; and

(c) filling a plurality of the particles into a capsule.

10. (Original) The pharmaceutical dosage form according to claim 9, wherein the drug substance is amorphous.

11. (Original) The pharmaceutical dosage form according to claim 9, wherein no greater than about 10 weight percent of the drug substance is crystalline.

12. (Original) The pharmaceutical dosage form according to claim 9, wherein compressing is conducted at about 0.2 tons to about 3 tons.

13. (Original) The pharmaceutical dosage form according to claim 9, wherein a maximum particle dimension is about 3 mm.

14. (Original) A method of preparing a pharmaceutical dosage form, comprising:

(a) forming a mixture comprising a drug substance that is susceptible to polymorphic conversion, with one or more pharmaceutically acceptable excipients; and

(b) compressing the mixture at about 0.2 tons to about 5 tons, to form particles.

15. (Original) The method according to claim 14, wherein particles have a maximum dimension no greater than about 3 mm.

16. (Original) The method according to claim 14, wherein the drug is amorphous.

17. (Original) The method according to claim 14, further comprising applying a coating to the particles.

18. (Original) The method according to claim 14, wherein compression is conducted at about 0.2 tons to about 3 tons.

19. (Original) The method according to claim 14, wherein a maximum dimension is about 1 mm to about 3 mm.

20. (Original) The method according to claim 14, further comprising placing a plurality of particles into a capsule.

21. (New) The tablet according to claim 1, wherein a drug substance comprises esomeprazole magnesium.

22. (New) The pharmaceutical dosage form according to claim 9, wherein a drug substance comprises esomeprazole magnesium.

23. (New) The method according to claim 14, wherein a drug substance comprises esomeprazole magnesium.